Q&A With Emmanuel Antonarakis, MD: AR-V7 “Liquid Biopsy” Can Avoid Unneeded Treatment, Curb Health Care Costs

from Prostate Cancer Advisor –

exosomesCancer Therapy Advisor spoke with Emmanuel S. Antonarakis, MD, associate professor of oncology at the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, about his team’s newly-published cost-savings analysis for a prostate cancer “liquid biopsy” that they have developed.

The test detects circulating tumor cell (CTC) expression of an androgen receptor (AR) gene-splice variant known as AR-V7. AR-V7 has been implicated in metastatic prostate tumor resistance to the androgen-receptor signaling (ARS) blockers abiraterone and enzalutamide. Whereas most candidate prostate cancer biomarkers are prognostic of patient outcomes, AR-V7 allows prediction of whether or ARS inhibition will be effective.1

Cancer Therapy Advisor (CTA): Your team has developed a clinical assay that detects AR-V7 messenger RNA (mRNA) in CTCs, a “liquid biopsy” that can predict likely treatment outcomes among patients with advanced castration-resistant prostate cancer (CRPC).

Now your team has published a cost-savings analysis that looked at how routine use of this test in the clinic can affect the cancer care costs for patients with advanced CRPC.

What did this analysis find, and what are the implications for clinical practice?  (read more…)

Leave a Reply

Your email address will not be published. Required fields are marked *

*